many plant waxes and plant extracts, such as those from Mucuna aterrima, Heliotropium subulatum, Haloxylon salicornicum and Phyllanthus amarus
443.3±8.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:593-50-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
Policosanols (PCs) are a mixture of long chain primary aliphatic alcohols mainly known for their ability to reduce cholesterol level. Due to this property, there is an increasing interest in the extraction process of these compounds. In this context, beeswax, a natural product produced by honey bees of the genus Apis, is a promising source for their extraction and purification. The present research work was aimed at the development of a new procedure for the extraction and purification of PCs from yellow beeswax by using microwave-assisted technology, which hitherto has never been applied to this mixture. The developed process comprises three main steps: 1) microwave-assisted trans-esterification; 2) microwave-assisted hydrolysis; 3) final purification by means of preparative liquid chromatography. The final step is responsible for the increased purity of PCs, thanks to the removal of undesired compounds, such as natural paraffins. The predominant alcohols investigated in this work are tetracosanol (C24OH), hexacosanol (C26OH), octacosanol (C28OH), triacontanol (C30OH) and dotriacontanol (C32OH). Compound identification was performed using GC-EI-MS, while GC-FID analysis was chosen for the quantification of the main fatty alcohols present in the product. This new method represents a useful tool for the production of PCs from beeswax to be used in pharmaceuticals and nutraceuticals for human use, feed and veterinary supplements.
Beeswax; Gas chromatography; Microwave-assisted extraction; Policosanols; Preparative liquid chromatography.
A new strategy based on microwave-assisted technology for the extraction and purification of beeswax policosanols for pharmaceutical purposes and beyond
Alberto Venturelli 1, Virginia Brighenti 2, Danilo Mascolo 3, Federica Pellati 4
2019 Aug 5;
1-Triacontanol (TRIA) is gaining a lot of interest in agricultural practice due to its use as bio-stimulant and different types of TRIA-containing products have been presented on the market. Up to date, TRIA determination is performed by GC analysis after chemical derivatization, but in aqueous samples containing low amounts of TRIA determination can be problematic and the derivatization step can be troublesome. Hence, there is the need for an analysis method without derivatization. TRIA-based products are in general plant extracts that can be obtained with different extraction procedures. These products can contain different ranges of concentration of TRIA from units to thousands of mg/kg. Thus, there is the need for a method that can be applied to different sample matrices like plant materials and different plant extracts. In this paper we present a HPLC-ELSD method for the analysis of TRIA without derivatization. The method has been fully validated and it has been tested analyzing the content of TRIA in different dried vegetal matrices, plant extracts, and products. The method is characterized by high sensitivity (LOD = 0.2 mg/L, LOQ = 0.6 mg/L) and good precision (intra-day: <11.2%, inter-day: 10.2%) being suitable for routine analysis of this fatty alcohol both for quality control or research purposes.
1-triacontanol; HPLC-ELSD; biostimulant; method validation.
Development and Validation of an HPLC-ELSD Method for the Quantification of 1-Triacontanol in Solid and Liquid Samples
Stefania Sut 1, Clizia Franceschi 2, Gregorio Peron 3, Gabriele Poloniato 4, Stefano Dall'Acqua 5
2018 Oct 26
Triacontanol (TA), a natural compound with various health benefits, is extensively used as a nutritional supplement. The therapeutic and nutraceutical applications of TA are limited due to its poor aqueous solubility. PEGylated triacontanol (PEGylated TA) was designed to improve the solubility and pharmacokinetics of TA. After PEGylation, the solubility (∼250 g·L-1 versus 9 × 10-14 g·L-1), body residence (MRT, 9.40 ± 2.03 h versus 2.59 ± 0.705 h, p < 0.001), and systemic exposure (AUC0-inf, 29.1 ± 5.33 μM·h versus 0.529 ± 0.248 μM·h, p < 0.001) of TA were all significantly increased compared to pristine TA. When intravenously administered (6.85, 22.8, and 68.5 μmol·kg-1) in rats, PEGylated TA exhibited a slow clearance (44.8 ± 8.62, 47.9 ± 5.18, and 46.9 ± 16.5 mL·h-1·kg-1), long elimination half-life (8.76 ± 0.96, 10.4 ± 1.66, and 11.1 ± 2.81 h), and abundant systemic exposure (AUC0- t, 155 ± 24.2, 523 ± 56.2, and 1709 ± 245 μM·h). Meanwhile, its metabolite TA showed a high AUC0- t (28.4 ± 5.14, 151 ± 25.4, and 797 ± 184 μM·h) and slow elimination ( t1/2, 10.1 ± 2.03, 7.78 ± 1.74, and 6.82 ± 0.58 h). Our results demonstrated that PEGylated TA has superior pharmacokinetics, which enhanced its nutritional and pharmacodynamic potency, and thus warrants further investigations.
GC-MS/MS; PEGylated triacontanol; pharmacokinetics; prodrug; triacontanol.
PEGylated Triacontanol Substantially Enhanced the Pharmacokinetics of Triacontanol in Rats
Ning Li 1 2, Xiaoyu Lu 3, Min Fang 3, Zhixia Qiu 4, Xijing Chen 3, LiLi Ren 2, Pingkai Ouyang 1, Guoguang Chen 2
2018 Aug 22;